VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice

Life Sciences

Volumn 74, Issue 11, 2004, Pages 1345-1357

  Moody, Terry W ^a   Dudek, James ^b   Zakowicz, Halina ^b   Walters, James ^b   Jensen, Robert T ^c   Petricoin, Emmanual ^d   Couldrey, Chris ^a   Green, Jeff E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Chemoprevention; Mammary carcinogenesis; Proteomics; Transgenic mice; VIP receptor antagonist

Indexed keywords

ANTISERUM; ARGININE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYBRID PROTEIN; IODINE 125; LEUCINE; LYSINE; RO 25 1553; TUMOR EXTRACT; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SURVIVAL; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; CYTOSOL; FEMALE; IMMUNOHISTOCHEMISTRY; MICRODISSECTION; MOUSE; NONHUMAN; PROTEIN BINDING; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE HOMOGENATE; TUMOR CELL; WESTERN BLOTTING;

ANIMALIA; MUS MUSCULUS;

EID: 0347360143     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.07.043     Document Type: Article

References (38)

1. Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): Discovery and current status of research. Regul. Peptides. 37(3):1992;287-303.
2. Bonner R.F., Emmert-Buck M., Pohida T., Chuaqui R., Goldstein S., Liotta L.A. Laser capture microdissection: Molecular analysis of tissue. Science. 278(5342):1997;1481-1483.
3. Clarke R. Animal models of breast cancer: Experimental design and their use in nutrition and psychosocial research. Breast Cancer Res. Treat. 46(2-3):1997;117-133.
4. Cronin W.M., Vogel V., Tovidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-I study. J. Natl. Cancer Inst. 90(18):1998;1371-1388.
5. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powldes T.J., Cauley J.A., Norton L., Nickelsen T., Bjarnason N.H., Morrow M., Lippman M.E., Black D., Glusman J.E., Costa A., Jordon V.C. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J. Am. Med. Assoc. 281(23):1999;1289-2197.
6. Dickson R.B., Lippman M.E. Molecular biology of breast cancer. DeVita V.T., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology. 1997;1541-1547 Lippincott-Raven Press, Philadelphia.
7. Ebina M., Steinberg S.A., Mulshine J.L., Linnoila I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 54(9):1994;2496-2503.
8. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Tovidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-I Study. J. Natl. Cancer Inst. 90(18):1998;1371-1388.
9. Gelber E., Granoth R., Fridkin M., Dreznik Z., Brenneman D.E., Moody T.W., Gozes I. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutics agents on cancer cell lines. Cancer. 92(8):2001;2172-2180.
10. Gespach C., Bawab W., Decremoux P., Calvo F. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer Res. 48(18):1988;5079-5083.
11. Gozes I., McCune S.K., Jacobson L., Warren D., Moody T.W., Fridkin M., Brenneman D.E. A hybrid antagonist to vasoactive intestinal peptide: Effects on cellular function in the central nervous system. J. Pharm. Exp.Ther. 257(3):1991;959-966.
12. Green J.E., Shibata M.A., Yoshidome K., Liu M., Jorcky C., Anver M.R., Wigginton J., Wiltrout R., Shibata E., Kaczmarczyk S., Wang W., Liu A., Calvo A., Couldrey C. The C3 (1)SV40 T-antigen transgenic mouse model of mammary cancer: Ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene. 19(18):2000;1020-1027.
13. Green J.E., Shibata M.A., Shibata E., Moon R.C., Anver M.R., Kelloff G., Lubet R. 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3 (1)/SV40T/T-antigen transgenic mice. Cancer Res. 61(20):2001;7449-7455.
14. Harmar T., Lutz E. Multiple receptors for PACAP and VIP. Trends in Pharmacological Sciences. 15(4):1993;97-99.
15. Ishihara R., Shigemoto R., Mori K., Takahashi K., Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron. 8(4):1992;811-819.
16. Landis S., Murray T., Bolden S., Wingo P.C.A. Cancer Statistics, 1999. CA Cancer, J. Clin. 49(1):1999;8-31.
17. Lee M., Jensen R.T., Huang S.C., Bepler G., Korman L., Moody T.W. Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cyclic AMP levels. Peptides. 11(6):1990;1205- 1209.
18. Leyton J., Purdom S., Cassibang M., Gozes Y., Zia F., Coy D., Moody T.W. PACAP(6-38) is a PACAP receptor antagonist for breast cancer cells. Breast Cancer Res. Treat. 56(2):1999;177-186.
19. Marshall L., Hunter D., Connolly J., Schnitt S., Byrne C., London S., Colditz C. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol. Biomarkers Prev. 6(5):1997;297-301.
20. McKenzie K., Sukumar S. Molecular genetics of human breast cancer. Huff J., Boyd J., Barrett J. Cellular and Molecular Mechanisms of Hormonal Carcinogenesis: Environmental Influences. 1996;183-209 Wiley-Liss Inc, New York.
21. Moody T.W., Leyton J., Gozes I., Lang L., Eckelman W.C. VIP and breast cancer. Ann. N.Y. Acad. Sci. 865:1998;290-296.
22. Moody T.W., Leyton J., Chan D., Brenneman D.C., Fridkin M., Gelber E., Levy A., Gozes I. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res. Treat. 68(1):2001;55-64.
23. Moon R.C., Constantinou A.I. Dietary retinoids and carotenoids in rodent models of mammary tumorigenesis. Breast Cancer Res. Treat. 46(2-3):1997;181-189.
24. Moon R.C., Grubbs C., Sporn M.B. Inhibition of 7,12-dimethylbenz(a) anthracene-induced mammary carcinogenesis by retinyl acetate. Cancer Res. 36(7PT2):1976;2626-2630.
25. Moon R.C., McCormick D., Mehta R.G. Inhibition of carcinogenesis by retinoids. Cancer Res. 43(S5):1983;2469s-2475s.
26. Pisegna J.R., Wank S.A. Molecular cloning and functional expression of the pituitary adenylate cyclase activating polypeptide type I receptor. Proc. Natl. Acad. Sci. USA. 90(13):1993;6345-6349.
27. Ram T.G., Kokeny K.E., Dilts C.A., Ethier S.P. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor I in human mammary epithelial cells. J. Cell Physiol. 163(3):1995;589-596.
28. Reubi J.C. In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging. J. Nucl. Med. 36(10):1995;1846-1853.
29. Reubi J.C. In vitro evaluation of VIP/PACAP receptors in healthy and diseases human tissues. Clinical implications. Ann. N.Y. Acad. Sci. 921:2000;1-30.
30. Reubi J.C., Laderach U., Waser B., Gebbers J.O., Robberecht P., Laissue J.A. Vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 60(11):2000;3105-3112.
31. Said S.I., Mutt V. Peptide with broad biological activity:Isolation from the small intestine. Science. 169(951):1970;1217-1218.
32. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeberg P.H., Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature. 365(6442):1993;170-175.
33. Tripathy D., Benz C. Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. Benz C., Liu E. Oncogenes and tumor suppressor genes in human malignancies. 1993;15-60 Kluwer Academic Publishers, Boston.
34. Waschek J.L., Richards M.L., Bravo D.T. Differential expression of VIP/PACAP receptor genes in breast, intestinal and pancreatic lines. Cancer Lett. 92(2):1995;143-149.
35. Wu K., Kim H.T., Rodriquez J.L., Munoz-Medellin D., Moshsin S.K., Hilsenbeck S.G., Lamph W.M., Gottardis M.M., Shirley M.A., Kuhn J.G., Green J.E., Brown P.H. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3 (1)-Simian Virus 40 T antigen-transgenic mice. Clin. Cancer Res. 6(9):2000;3696-3704.
36. Wulfkuhle J.D., McLean K.C., Paweletz C.P., Sgroi D.C., Trock B.J., Steeg P.S., Petricoin E.F. New approaches to proteomic analysis of breast cancer. Proteomics. 1(10):2001;1205-1215.
37. Wulfkuhle J.D., Sgroi D.C., Krutzsch H.J., McLean K., McGarvey K., Knowlton M., Chen S., Shu H., Sahin A., Kurek R., Wallwiener D., Merino M.J., Petricoin E.F., Zhao Y., Steeg P.S. Proteomics of human breast ductal carcinoma in situ. Cancer Res. 62(22):2002;6740-6749.
38. Zia H., Hida T., Jakowlew S., Birrer M., Gozes Y., Reubi J.C., Fridkin M., Gozes I., Moody T.W. Breast cancer growth is inhibited by VIPhybrid, a synthetic VIP receptor antagonist. Cancer Res. 56(15):1996;3486-3489.